511 results on '"Samuel S Lee"'
Search Results
2. Treatment Outcomes with Telaprevir-Based Therapy for HIV/Hepatitis C Coinfected Patients are Comparable with Hepatitis C Monoinfected Patients
3. Rituximab for the Treatment of Patients with Autoimmune Hepatitis Who are Refractory or Intolerant to Standard Therapy
4. Canadian Patients with Chronic Hepatitis B Cannot Access Appropriate Drug Treatments: A Call for Change
5. Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
6. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
7. Impact of Pharmaceutical Industry Versus University Sponsorship on Survey Response: A Randomized Trial among Canadian Hepatitis C Care Providers
8. Emergency Management of Bleeding Esophageal Varices: Drugs, Bands or Sleep?
9. Acute Management and Secondary Prophylaxis of Esophageal Variceal Bleeding: A Western Canadian Survey
10. Correction: Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients During Pregnancy and Post-Partum Follow-up.
11. Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients during Pregnancy and Post-Partum Follow-Up.
12. Reactivation of Hepatitis B e Antigen-Negative Chronic Hepatitis B in a Bone Marrow Transplant Recipient following Lamivudine Withdrawal
13. Hemodynamic Characterization of Arterialized and Nonarterialized Liver Transplants in the Rat
14. Clinical outcomes of esophageal squamous cell carcinoma in patients with cirrhosis
15. Reply to: Correspondence on 'Cardiomyopathy in cirrhosis: From pathophysiology to clinical care'
16. Chronic Hepatitis C in Western Canada: A Survey of Practice Patterns among Gastroenterologists in Alberta and British Columbia
17. Hepatitis C Diagnosis and Treatment Among Indigenous People in a Canadian Context: Challenges and Community-Led Solutions
18. Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue.
19. Failure of Splenectomy to Ameliorate Portal Hypertension in Myeloproliferative Disorders
20. Fatal Hepatic Decompensation in a Patient with Hepatitis B Cirrhosis Following Famciclovir Withdrawal
21. Autonomic Regulation of Splanchnic Circulation
22. Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
23. Liver Transplantation for Alcoholic Liver Disease: A Devilish Dilemma
24. Pay Now or Pay (more) Later: Tracking the Costs of Hepatitis C Infection
25. Acute Coinfection with Hepatitis B and Hepatitis C Viruses
26. Vasopressin Antagonists and Dilutional Hyponatremia
27. Hepatitis C Virus Infection in Canada’S First Nations People: A Growing Problem
28. Hepatitis C, Insulin Resistance and Fatty Liver: Bad Things Come in Threes
29. Cardiomyopathy in cirrhosis: From pathophysiology to clinical careKey points
30. To B or Not to B: How Is Hepatitis B Spread and What Can be Done?
31. Prolonged QT Interval in Cirrhosis: Twisting Time?
32. Role of Galectin in Cardiovascular Conditions including Cirrhotic Cardiomyopathy
33. Dysregulated Calcium Handling in Cirrhotic Cardiomyopathy
34. Engineering Large-Area Antidust Surfaces by Harnessing Interparticle Forces
35. Impact of direct‐acting antiviral treatment on health utility in patients with chronic hepatitis C in hospital and community settings
36. Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats
37. Review article: diagnosis, pathophysiology and management of atrial fibrillation in cirrhosis and portal hypertension
38. Recent Advances in Organ‐on‐Chips Integrated with Bioprinting Technologies for Drug Screening
39. Impact of the COVID-19 Pandemic on Hospitalizations for Alcoholic Hepatitis or Cirrhosis in Alberta, Canada
40. Patient‐specific genetic factors predict treatment failure in sofosbuvir‐treated patients with chronic hepatitis C
41. Figure S7 from Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity
42. Supplementary Data from Restricted Expression of miR-30c-2-3p and miR-30a-3p in Clear Cell Renal Cell Carcinomas Enhances HIF2α Activity
43. A randomized controlled trial of SOF/VEL/VOX with or without ribavirin for retreatment of chronic hepatitis C
44. A real-world retrospective single-centre study of the cost-effectiveness and long-term outcomes of pegylated interferon for chronic hepatitis B
45. Effects of Vasoactive Drugs on the Systemic and Splanchnic Circulation
46. The Heart in Liver Disease
47. Preface
48. The liver–heart relationship: a history
49. List of contributors
50. Cirrhotic cardiomyopathy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.